Comparing biomarkers in regular cannabis users and non-users to find signs of recent inhalation
Official title: CANBiome: Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users
Run by University of Basel · NCT06975020 · Data updated 2026-11-12
We will test whether specific blood or other biological markers can indicate how recently regular cannabis smokers last inhaled by comparing them with non-users.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of Basel Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | December 19, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT06975020 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–65 who smoke cannabis about once a week (may mix with tobacco), hold a driving license, speak German, and can avoid cannabis, nicotine, and alcohol before the visit.
✕Probably not a fit
People with current or past major psychiatric disorders, pregnant or breastfeeding individuals, those taking strong CYP2C9/2C19/3A4 inducers or inhibitors, or people who do not match the regular-use or non-use groups are unlikely to gain direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot interventional study recruits regular cannabis smokers and a comparison group of non-users to search for markers that approximate the timing of the last inhalation. Participants will prepare and inhale their usual cannabis product (up to 15 minutes) and provide blood and possibly other biological samples for measurement of THC, metabolites, and candidate biomarkers. The study focuses on factors that might explain individual differences in THC pharmacokinetics and pharmacodynamics. Results will guide future research to better distinguish impaired from unimpaired cannabis users in road-traffic settings.
Why it matters
Potential benefit: If successful, the study could identify objective markers that help determine how recently someone inhaled cannabis, improving road-safety decisions and legal guidance.
How similar studies have gone: Previous research has shown that THC blood levels poorly predict impairment and studies of alternative markers are limited and have not yet produced a reliable, widely accepted test.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Experience of smoking cannabis products, on average once a week. This may be in combination with tobacco. * Age 18-65 years Possession of driving license in at least one of the categories A, B, A1; B1, F, G or M * Sufficient knowledge of German * No cannabis inhalation or nicotine consumption on study day * No alcohol consumption within the last 24 h Exclusion Criteria: * Participation in a trial with investigational drugs within 30 days * Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder) * Pregnancy or breastfeeding * Intake of CYP2C9, CYP2C19, and CYP3A4-inducers in the last 4 weeks before the study visit, e.g. rifampicin (antibiotic), carbamazepine (anticonvulsant), phenobarbital (anticonvulsant), phenytoin (anticonvulsant) or inhibitors, such as amiodarone (class III antiarrhythmic medication), antifungal drugs such as fluconazole, miconazole, voriconazole and itraconazole, antibiotics such as clarithromycin and sulfamethoxazole, ritonavir (protease inhibitor) and grapefruit juice. * The following conditions: vasopressin deficiency, pituitary tumor, active malignancy, severe hyponatremia requiring treatment, congestive heart failure, liver cirrhosis.
Where it's running
-
Insitute of forensic medicine
Basel, Switzerland Recruiting
Study contacts
- Study coordinator: Urs Duthaler, PhD
- Email: canbiome-studie@unibas.ch
- Phone: +41612673889
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of cannabis and tobacco on driving and cognition
This study tests how smoking or vaping cannabis and tobacco affects driving skills and thinking abilities in adults who use both substances.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.